Phase 3 Trials Test Upadacitinib for Moderately to Severely Active UC or CD

Phase 3 Trials Test Upadacitinib for Moderately to Severely Active UC or CD
Two global Phase 3 trials are evaluating upadacitinib as a potential treatment for adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC). The studies will evaluate the safety and efficacy of AbbVie’s therapy. Both are multi-center, double-blind and placebo-controlled. Patient enrollment is ongoing at CB Flock Research Corp. in Mobile, Alabama, for the UC trial (NCT03653026), and at several locations in the CD trial (NCT03345836). Some locations have yet to open. Upadacitinib (ABT-494) is an investigational oral treatment that belongs to a class of compounds called JAK inhibitors. By blocking the actions of the JAK family of signaling proteins, these molecules reduce pro-inflammatory and autoimmune responses. The UC trial, named U-Accomplish, will compare upadacitinib to placebo in inducing clinical remission at week eight, as assessed by the Adapted Mayo score. Another outcome measure at week eight will be the proportion of participants with endoscopic improvement or remission, defined as endoscopic subscore lesser than or equal to one or equal to zero, respectively. Other measures at that time will include the proportion of participants with no bowel urgency or abdominal pain; histologic improvement, mucosal healing, UC-related surgeries or hos
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *